Ipsen has expanded its R&D pipeline once again, agreeing a $1.8 billion alliance with Skyhawk Therapeutics focused on the development of RNA-targeting therapies for rare neurological diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback